Table V.

Effect of chemotherapy regimens on the survival of pancreatic cancer patients.

Parameter	No.	Median survival (months; 95% CI)	P-value	Hazard ratio (95% CI)
Multi-drug vs. single-drug regimen
Multi-drug	58	7.6 (6.0–10.0)
Single-drug	35	7.6 (4.2–15.6)	0.743	0.92 (0.57–1.49)
Gemcitabine, fluorouracil and combined regimen
Gemcitabine	50	7.6 (6.0–14.2)
Fluorouracil	25	5.0 (3.7–10.0)
Combined	18	9.3 (7.1–11.0)	0.364	1.09 (0.90–1.32)
Gemcitabine
Yes	68	9.0 (7.1–11.0)
No	25	5.0 (3.7–10.0)	0.956	0.99 (0.58–1.68)
Fluorouracil
Yes	43	7.4 (4.5–10.0)
No	50	7.6 (6.0–14.2)	0.504	1.17 (0.74–1.84)
Platinum (1)
With	48	10.0 (7.6–14.0)
Without	47	5.0 (3.2–7.1)	0.011	0.56 (0.35–0.88)
Platinum (2)
Cisplatin	8	7.9 (5.1–17.0)
Carboplatin	15	9.6 (6.0–17.3)
Oxaliplatin	23	12.4 (10.0–19.0)	0.093	0.70 (0.46–1.06)